U.S. Markets open in 4 hrs 44 mins

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.5100-0.1400 (-3.84%)
At close: 4:00PM EDT

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas
28th Floor
New York, NY 10019
United States
201 488 0460

Full Time Employees40

Key Executives

NameTitlePayExercisedYear Born
Mr. Chaim LebovitsChief Exec. Officer1.64MN/A1971
Dr. Irit Arbel Ph.D., DScCo-Founder & Independent Vice Chair of the BoardN/AN/A1960
Dr. Ralph Z. KernPres & Chief Medical Officer844.22kN/A1958
Mr. Uri YablonkaExec. VP, Chief Bus. Officer, Sec. & DirectorN/AN/A1977
Dr. Preetam Shah M.B.A., Ph.D.Exec. VP, CFO & TreasurerN/AN/A1973
Dr. David Setboun M.B.A., Pharm.D.Exec. VP & COON/AN/A1975
Dr. Yael GothelfVP of Scientific & Regulatory AffairsN/AN/AN/A
Dr. Daniel OffenChief Scientific AdvisorN/AN/AN/A
Mr. Arturo O. ArayaChief Commercial OfficerN/AN/A1971
Dr. Stacy R. Lindborg Ph.D.Exec. VP & Head of Global Clinical ResearchN/AN/A1971
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Corporate Governance

Brainstorm Cell Therapeutics Inc.’s ISS Governance QualityScore as of April 1, 2021 is 6. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.